Vertex Pharmaceuticals
VRTX
814 hedge funds and large institutions have $53.4B invested in Vertex Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 165 funds opening new positions, 277 increasing their positions, 266 reducing their positions, and 41 closing their positions.
302% more first-time investments, than exits
New positions opened: 165 | Existing positions closed: 41
28% more capital invested
Capital invested by funds: $41.8B → $53.4B (+$11.7B)
15% more funds holding
Funds holding: 708 → 814 (+106)
4% more repeat investments, than reductions
Existing positions increased: 277 | Existing positions reduced: 266
0% more funds holding in top 10
Funds holding in top 10: 18 → 18 (0)
0.98% less ownership
Funds ownership: 95.92% → 94.94% (-0.98%)
5% less call options, than puts
Call options by funds: $369M | Put options by funds: $388M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$656M |
| 2 |
Renaissance Technologies
New York
|
+$259M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$117M |
| 4 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$96.7M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$90.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$519M |
| 2 |
Jennison Associates
New York
|
-$487M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$357M |
| 4 |
ClearBridge Investments
New York
|
-$180M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$176M |
VRTX Hedge Fund Activity: Q4 2019 in Review
814 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q4 2019, worth a combined $53.4B — up 28% from $41.8B a quarter earlier.
Buyers outnumbered sellers: 165 funds opened new VRTX positions and 41 closed out — a net gain of 124 holders — while 277 added to existing stakes and 266 trimmed.
The largest buyer was Capital International Investors, adding an estimated $656M. The largest seller was Invesco, cutting an estimated $519M.
- 814 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q4 2019, up from 708 in Q3 2019.
- Funds reported $53.4B of Vertex Pharmaceuticals stock for Q4 2019, up 28% quarter-over-quarter.
- 165 funds opened new Vertex Pharmaceuticals positions in Q4 2019 and 41 closed out, a net change of +124 holders.
- The largest Vertex Pharmaceuticals buyer in Q4 2019 was Capital International Investors, an estimated $656M added.
- The largest Vertex Pharmaceuticals seller in Q4 2019 was Invesco, an estimated $519M sold.
Based on aggregated 13F filings for Q4 2019.